Rocket Lab Execs Sold $27M Ahead of Neutron Gains
Five senior executives sold $26.96 million at $62 to $72 over 90 days preceding a 15% stock rally and Neutron development advances. At the current $54.73 price, the stock trades 14-23% below all insid
Rocket Lab Execs Sold $27M Ahead of Neutron Gains
NEW YORK, October 30 —
Rocket Lab Corporation (RKLB) shares advanced 15% over five sessions, with an additional after-hours move on October 28 following a Neutron development update, yet five senior executives had already sold $26.96 million at $62 to $72 over the preceding 90 days. At $54.73, the stock trades below every insider exit price from that period.
- Five executives sold $26.96M at $62.26 to $71.79 over 90 days; zero insider purchases recorded.
- At $54.73, the stock trades 14% to 23% below all insider sale prices from the period.
- Analyst consensus target of $102.15 implies approximately 87% upside; stock remains down 17% year-to-date in 2026.
Eleven Days After the Filing
On August 13, 2026, Rocket Lab filed a 424B5 prospectus supplement, three days after reporting quarterly earnings. Eleven days later, five executives sold simultaneously at $69.53 to $71.17: CFO Adam Spice, COO Frank Klein, President Marvin Bradford Clevenger, SVP and General Counsel Arjun Kampani, and VP Corporate Controller Agostino Ricupati. CFO Spice then liquidated 140,157 shares on September 2 at $62.26 to $62.97 and 140,157 more on October 1 at $70.28 to $71.79, each time pairing the sale with a same-day option exercise at $1.09. The $62 to $72 range now represents supply overhead the current $54.73 price has not yet approached.
Why $62 Still Matters at $54
The same-day exercise-and-sell mechanics (options in at $1.09, stock out at market) are standard for executives with vested grants and often pre-scheduled under 10b5-1 plans. But five insiders selling across a single three-day window in late August, none buying, with the stock subsequently trading 14% to 23% below their exits, raises a plain question: why were the executives with the most direct view of Neutron's progress cutting exposure rather than adding it? Analyst consensus points to $102.15, yet the executives who know the business best exited above that level and bought nothing.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| RKLB | $35.0B | 952.0x | -6.2% |
| ASTS | $15.9B | n/a | -46.3% |
| NBIS | $39.1B | n/a | +31.5% |
| IONQ | $12.9B | n/a | -49.2% |
| IREN | $9.7B | n/a | -56.8% |
| CRWV | $30.3B | n/a | -54.6% |
The Milestone That Resolves Nothing Yet
Rocket Lab operates two segments: Electron launches and a space systems business covering spacecraft design, components, and constellation management. Trailing revenue reached $770 million, up 62% year-over-year, but the bull case for the stock has always been Neutron, the medium-class rocket targeting large constellation deployments and potentially human spaceflight. After three consecutive earnings beats, the most recent quarter produced a miss. The next earnings release will show whether the business can grow into its analyst target; use the DCF calculator to test what discount rate makes it work. Run the free Rocket Lab Corporation deep-dive to track the numbers.
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Frequently Asked Questions
How much stock did Rocket Lab executives sell?
Five senior executives sold $26.96 million at prices ranging from $62.26 to $71.79 over a 90-day period. The executives were CFO Adam Spice, COO Frank Klein, President Marvin Bradford Clevenger, SVP Arjun Kampani, and VP Agostino Ricupati. CFO Spice executed multiple same-day option exercises paired with stock sales in September and October.
Why does insider selling matter to investors?
Insiders have the deepest operational visibility into company progress. In this case, five executives reduced exposure at $62-$72 without purchasing shares, while analyst consensus targets $102.15, raising questions about the disconnect between insider actions and Wall Street expectations.
When did Rocket Lab executives sell their stock?
Five executives sold simultaneously on August 24 at $69.53 to $71.17, eleven days after the company filed a prospectus supplement. CFO Adam Spice made additional sales on September 2 and October 1, timing each transaction with a same-day option exercise at $1.09.
What does Rocket Lab do?
Rocket Lab operates two segments: Electron launches and a space systems business covering spacecraft design, components, and constellation management. The company's growth narrative centers on Neutron, a medium-class rocket targeting large constellation deployments and potentially human spaceflight.
What is Rocket Lab's revenue and earnings trend?
Trailing revenue reached $770 million, up 62% year-over-year, demonstrating strong growth. However, after three consecutive quarterly earnings beats, the most recent quarter produced a miss, raising questions about sustaining that growth trajectory.
Rocket Lab shares rose after hours on Neutron development progress, yet five senior executives sold a combined $26.96 million in stock at $62–$72 over the preceding 90 days with zero purchases — all at prices well above the current $54.73. The stock has logged a 15% five-day winning streak but remains down 17% year-to-date in 2026.